Please login to the form below

Not currently logged in
Email:
Password:

SCC

This page shows the latest SCC news and features for those working in and with pharma, biotech and healthcare.

Lilly closes on US approval of lung cancer drug necitumumab

Lilly closes on US approval of lung cancer drug necitumumab

They concluded that the drug provided a "modest but significant" benefit in this form of cancer, sometimes referred to as squamous cell carcinoma (SCC). ... About 25% to 30% of all lung cancers are SCCs, and these tend to be aggressive with less than 5%

Latest news

  • Boehringer plans new filings for Giotrif in lung cancer Boehringer plans new filings for Giotrif in lung cancer

    Boehringer Ingelheim is in the process of drawing up regulatory filings for its Giotrif product in squamous cell carcinoma of the lung (SCC) after reporting positive phase III data. ... SCC is a subgroup of non-small cell lung cancer (NSCLC), the most

  • Ensuring light for all

    practice. For each of the top five trusts, Ash developed a separate news release which included quotes from the SCC and CEO of the trusts. ... To support public affairs activity, Ash has issued releases outlining MPs' involvement targeting the national

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics